Publications
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma
Vanbervliet-Defrance B, Delaunay T, Daunizeau T, Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M, Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF, Lebecque S, Mahtouk K.
Cancer Lett. 2019 Dec 12. pii: S0304-3835(19)30622-6. doi: 10.1016/j.canlet.2019.12.016
Corrigendum to “Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis” [J Hepatol 71 (2019) 763-772]
2. Bonnin M, Fares N, Testoni B, Estornes Y, Weber K, Vanbervliet B, Lefrançois L, Garcia A, Kfoury A, Pez F, Coste I, Saintigny P, Viari A, Lang K, Guey B, Petrilli V, Hervieu V, Bancel B, Bartosch B, Durantel D, Renno T, Merle P, Lebecque S
J Hepatol. 2019 Nov 25. pii: S0168-8278(19)30651-8. doi: 10.1016/j.jhep.2019.11.001.
Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.
Alkurdi L, Virard F, Vanbervliet B, Weber K, Toscano F, Bonnin M, Le Stang N, Lantuejoul S, Micheau O, Renno T, Lebecque S, Estornes Y.
Cell Death Dis. 2018 Aug 29; 9(9):874
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
Hum Pathol. 2016 Jun;52:9-18.
Cleaved/associated TLR3 represents the primary form of the signaling receptor.
Toscano F, Estornes Y, Virard F, Garcia-Cattaneo A, Pierrot A, Vanbervliet B, Bonnin M, Ciancanelli MJ, Zhang SY, Funami K, Seya T, Matsumoto M, Pin JJ, Casanova JL, Renno T, Lebecque S.
J Immunol. 2013 Jan 15; 190(2):764-73.
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8.
Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pachéco Y, Salaun B, Renno T, Micheau O, Lebecque S.
Cell Death Differ. 2012 Sep;19(9):1482-94
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.
Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, Goubar A, Lebecque S, Pierres M, Rimoldi D, Romero P, Andre F.
Cancer Res. 2011 Mar 1;71(5):1607-14. doi: 10.1158/0008-5472.CAN-10-3490. Epub 2011 Feb 22.
Toll-like receptors two-edged sword: when immunity meets apoptosis.
Salaun B, Romero P, Lebecque S.
Eur J Immunol. 2007 Dec;37(12):3311-8.
Toll-like receptor 3 expressed by melanoma cells as a target for therapy?
Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P.
Clin Cancer Res. 2007 Aug 1; 13(15 Pt 1):4565-74
TLR3 can directly trigger apoptosis in human cancer cells.
Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T.
J Immunol. 2006 Apr 15;176(8):4894-901.
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.).
Lacour J, Laplanche A, Delozier T, Berlie J, Mourali N, Julien JP, De Gislain C, Namer M, Petit JC, Denis V, et al.
Breast Cancer Res Treat. 1991 Sep;19(1):15-21.
Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer.
Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, Sarrazin D, Contesso G, Viguier J.
Lancet. 1980 Jul 26;2(8187):161-4.
Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE